Routine demat compliance certificate filed for Q2 FY26

Compliance View source PDF Explain this filing

VAISHALI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹7.78

prior close

₹7.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+0.3% vs market

Pharmaceuticals peers, median of 173sector+0.0%+1.0% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-1.9

15m

-1.9

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.7+0.3+0.0+1.0

Next day

-3.6-1.0-2.6-1.2-2.4

-5.7-3.6-2.1-2.8-2.8

-7.5-4.5-2.9-3.8-3.7

-11.7-6.8-4.9-5.0-6.7

-11.6-6.4-5.2-3.9-7.6

-12.5pendingpending-0.9-11.6

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vaishali Pharma submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 September 2026. The company's registrar Bigshare Services confirmed the regulation does not apply as 100 percent of shares are already held in demat form and no dematerialisation or rematerialisation requests were received during the quarter.

Likely market impact

No impact on shareholders or stock price. This is a standard regulatory filing with no material information.